Hi Kild,
Large professional investors and the market generally understand how molecular biotech business models work, the strategic plan for the commercialisation of their products, and they know that early sales are relatively meaningless within such a plan.
Early random sales achieved, whilst engaging and training sales staff, and establishing a contact base for much more lucrative user programme roll overs, are certainly not an indicator of progress, nor are they at all indicative of a stock’s valuation.
A read of these links may serve you well, there is a methodology applied by analysts in valuing biotech stocks,
https://www.deloitte.com/view/en_us/...42f00aRCRD.htm
http://www.investopedia.com/articles...hvaluation.asp
Genuinely hope this assists you
kind regards, Mac